在我國(guó)絕大多數(shù)藥物晶型研究仍處于隨意和偶然的自發(fā)研究狀態(tài)。仿制藥物療效低于原研產(chǎn)品，創(chuàng)新藥物質(zhì)量不穩(wěn)定的主要原因之一就是晶型問(wèn)題。因此，更好地控制多晶型、利用多晶型，提高藥品的穩(wěn)定性，從而確保藥品的安全有效性。綜述了晶型對(duì)藥物穩(wěn)定性的影響因素、抑制轉(zhuǎn)晶、亞穩(wěn)定型穩(wěn)定化方法等的研究進(jìn)展。

The majority of drug crystal research in China is still in the casually and occasionally spontaneous status. The curative effect of generic drug is lower than that of original one and the instability of innovative drug is mainly due to the form of crystalline. Therefore, in order to control the polymorphs, use polymorph better, and improve the stability of drugs, so that the safety and effectiveness of drugs are ensured. This paper reviewed the issues affecting crystal on the drug stability factors, inhibiting the crystallization and metastable type stabilization method and so on.